Aurinia Pharmaceuticals Inc (AUPH)
5.085
+0.04
(+0.69%)
USD |
NASDAQ |
Apr 23, 16:00
5.085
0.00 (0.00%)
After-Hours: 20:00
Aurinia Pharmaceuticals Enterprise Value: 384.89M for April 23, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| April 23, 2024 | 384.89M |
| April 22, 2024 | 379.83M |
| April 19, 2024 | 371.15M |
| April 18, 2024 | 345.12M |
| April 17, 2024 | 359.58M |
| April 16, 2024 | 372.60M |
| April 15, 2024 | 378.38M |
| April 12, 2024 | 387.06M |
| April 11, 2024 | 384.17M |
| April 10, 2024 | 371.15M |
| April 09, 2024 | 388.51M |
| April 08, 2024 | 369.71M |
| April 05, 2024 | 379.83M |
| April 04, 2024 | 385.62M |
| April 03, 2024 | 398.63M |
| April 02, 2024 | 384.17M |
| April 01, 2024 | 430.45M |
| March 28, 2024 | 374.05M |
| March 27, 2024 | 372.60M |
| March 26, 2024 | 362.48M |
| March 25, 2024 | 371.15M |
| March 22, 2024 | 368.26M |
| March 21, 2024 | 374.05M |
| March 20, 2024 | 392.85M |
| March 19, 2024 | 398.63M |
| Date | Value |
|---|---|
| March 18, 2024 | 385.62M |
| March 15, 2024 | 397.18M |
| March 14, 2024 | 385.62M |
| March 13, 2024 | 408.75M |
| March 12, 2024 | 401.52M |
| March 11, 2024 | 426.11M |
| March 08, 2024 | 434.79M |
| March 07, 2024 | 437.68M |
| March 06, 2024 | 447.80M |
| March 05, 2024 | 459.37M |
| March 04, 2024 | 482.51M |
| March 01, 2024 | 485.40M |
| February 29, 2024 | 476.72M |
| February 28, 2024 | 494.08M |
| February 27, 2024 | 520.11M |
| February 26, 2024 | 517.22M |
| February 23, 2024 | 509.99M |
| February 22, 2024 | 517.22M |
| February 21, 2024 | 479.62M |
| February 20, 2024 | 457.92M |
| February 16, 2024 | 495.53M |
| February 15, 2024 | 520.11M |
| February 14, 2024 | 802.11M |
| February 13, 2024 | 768.53M |
| February 12, 2024 | 846.20M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
207.43M
Minimum
Dec 27 2022
4.000B
Maximum
Oct 29 2021
1.184B
Average
1.176B
Median
Mar 30 2023
Enterprise Value Benchmarks
| Lexaria Bioscience Corp | 23.70M |
| Acasti Pharma Inc | 1.956M |
| Edesa Biotech Inc | 9.894M |
| Xenon Pharmaceuticals Inc | 2.461B |
| ESSA Pharma Inc | 148.52M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -26.88M |
| Revenue (Quarterly) | 45.10M |
| Total Expenses (Quarterly) | 74.77M |
| EPS Diluted (Quarterly) | -0.18 |
| Gross Profit Margin (Quarterly) | 88.04% |
| Profit Margin (Quarterly) | -59.60% |
| Earnings Yield | -10.42% |
| Normalized Earnings Yield | -10.42 |